SEATTLE, March 28 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced that the filing of its annual report on Form 10-K for the year ended December 31, 2007 has now been timely completed. This filing is available for review on CTI's Web site at http://www.CellTherapeutics.com or on the Securities and Exchange Commission's Web site at http://www.sec.gov.
As required under Nasdaq Marketplace Rule 4350(b)(1)(B), CTI also announced that its independent auditor's report included in the annual report on Form 10-K contains a "going concern" qualification.
About Cell Therapeutics, Inc.
Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.
media@ctiseattle.comhttp://www.CellTherapeutics.com/media.htminvest@ctiseattle.comhttp://www.CellTherapeutics.com/investors.htm
CONTACT: media, Dan Eramian, +1-206-272-4343, cell, +1-206-854-1200,
media@ctiseattle.com, or investors, Leah Grant, +1-206-282-7100, fax,
+1-206-272-4434, invest@ctiseattle.com, both of Cell Therapeutics, Inc.
Web site: http://www.CellTherapeutics.com/
